Egetis Therapeutics AB (publ)
The answer first
Does Egetis Therapeutics beat the market?
Yes, Egetis Therapeutics has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 43% of Nordic stocks
- Quality45
- Value2
- Trend99
No. 77 of 195 in healthcare
Max for seven days
Follow Egetis Therapeutics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Egetis Therapeutics
Your first answer is free, no account needed.
Do you own Egetis Therapeutics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Egetis Therapeutics and a few more. Free, no card.
Super Stock+44.6%In short
- Egetis Therapeutics has risen 100.4% over the past year, including dividends.
- Overall, Egetis Therapeutics ranks better than 43% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 67.0%. The price is 79.0% below its peak now.
What do analysts think of Egetis Therapeutics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 43% of Nordic stocks.
No. 77 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 138 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.25
- Asset turnoverSales divided by everything the company owns0.11
- Return on equityProfit divided by equity−138.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 181 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity15.4
- P/SPrice divided by sales74.7
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 4 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+52.0%
- 6 months+76.0%
- 9 months+136.5%
- 12 months+100.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Egetis Therapeutics
10 funds we follow own Egetis Therapeutics. The share is how much of the fund the stock makes up.
- Norway1
- Sweden9
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo2.0%
- PLUS Mikrobolag Sverige IndexSweden · PLUS1.7%
- PLUS Hälsovård Sverige IndexSweden · PLUS0.7%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest0.5%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest0.5%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.1%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
From the funds' latest known holdings.
About Egetis Therapeutics
Egetis Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 61 employees.
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.


See the full analysis of Egetis Therapeutics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card